| DB ID | MyCo_1930 |
| Title | Detection of Candida albicans Sap2 in cancer patient serum samples by an indirect competitive enzyme-linked immunosorbent assay for the diagnosis of candidiasis |
| Year | 2013 |
| PMID | 24152501 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | Cancer |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. |
| Site of Infection | None |
| Opportunistic invasive | Invasive/Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Sap2 |
| Biomarker Full Name | Secreted aspartyl proteinases 2 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | A total of 286 patients (129 men and157 women) with cancer were enrolled in this study. |
| Cohort No. | 286 |
| Age Group | 29-91 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
